Clinical outcomes among patients treated with Lu-PSMA-617 and metastasis-directed EBRT for metastatic prostate cancer.

Pluvicto (lutetium Lu 177 vipivotide tetraxetan) - Novartis

http://www.ncbi.nlm.nih.gov/pubmed/42744074

Elio Adib; Emerson Lee; Hailey Stoltenberg; Heather Jacene; Joseph H Killoran; Kirti Menon; Mai Anh Huynh; Praful Ravi; Yu-Hui Chen

Sep 16, 2026